Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-T1D-1: Tirzepatide in Type 1 Diabetes and Obesity or Overweight
NCT06914895Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of tirzepatide in type 1 diabetes mellitus (T1D), obesity, Overweight, sponsored by Eli Lilly and Company. Started Apr 2025; status: active, not recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)obesityOverweight
Beyond the preview
Go deeper on NCT06914895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914895.